Review
Oncology
Lin Tang, Rui Zhang, Xiaoyu Zhang, Li Yang
Summary: In the past few decades, there has been significant progress in the clinical application of DC vaccines loaded with personalized neoantigens, showing potential as safe and effective treatment strategies in patients with melanoma and glioblastoma. Despite their stability and safety, there are still various factors limiting the effectiveness of DC vaccines.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Jie Zhang, Biao Fan, Guoliang Cao, Wenping Huang, Fuhao Jia, Guangjun Nie, Hai Wang
Summary: This study developed a personalized DC-mimicking nanovaccine for stimulating TAAs-specific T cell populations. By inducing BMDCs maturation and delivering TAAs through nanostructures, the nanoDCs efficiently generated potent antigen-specific T cell responses, leading to inhibition of tumor growth and metastases formation.
ADVANCED MATERIALS
(2022)
Review
Biochemistry & Molecular Biology
Zaoqu Liu, Jinxiang Lv, Qin Dang, Long Liu, Siyuan Weng, Libo Wang, Zhaokai Zhou, Ying Kong, Huanyun Li, Yilin Han, Xinwei Han
Summary: Immunotherapy treatments using the immune system have revolutionized personalized medicine and brought significant benefits for cancer patients. Tumor neoantigens, arising from somatic mutations and presented by major histocompatibility complex, play a crucial role in immunotherapy. With advancements in sequencing technology and bioinformatics, the identification of neoantigens has accelerated and is expected to be integrated into clinical practice. Neoantigen vaccines, such as peptides, DNA, RNA, and dendritic cells, have shown great potential in activating specific T cells and enhancing anti-tumor immunity. This review discusses the origin and prediction of neoantigens, compares different types of neoantigen vaccines, and explores strategies for improving their efficacy, while addressing the challenges in their application.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Oncology
Erkko Ylosmaki, Manlio Fusciello, Beatriz Martins, Sara Feola, Firas Hamdan, Jacopo Chiaro, Leena Ylosmaki, Matthew J. Vaughan, Tapani Viitala, Prasad S. Kulkarni, Vincenzo Cerullo
Summary: The study developed a novel cancer vaccine platform based on BCG, which can broaden immune responses to include tumor antigens. Coating BCG with tumor-specific peptides improved antitumor immune responses and increased the number of responders to anti-PD-1 immunotherapy when combined with ICI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Long-Bin Jeng, Li-Ying Liao, Fu-Ying Shih, Chiao-Fang Teng
Summary: This review summarizes the evidence from clinical trials and recent preclinical studies on dendritic cell (DC)-based vaccines as mono- or combination immunotherapy for treating hepatocellular carcinoma (HCC). DCs, as the most potent antigen-presenting cells in the human immune system, play an important role in activating immune responses against tumor cells. DC-based vaccines have been developed as a promising personalized cancer immunotherapy. This review provides a comprehensive summary of the evidence from clinical trials and preclinical studies on the safety, feasibility, and efficacy of DC-based vaccines in treating HCC patients and highlights the development of strategies for optimizing the efficacy of DC-vaccine-based immunotherapy for HCC.
Article
Biochemistry & Molecular Biology
Grzegorz Dyduch, Apolonia Miazek, Lukasz Laskowicz, Joanna Szpor
Summary: Treatment options for endometrial cancer are not satisfactory for advanced cases, leading to interest in novel immunological therapies. This study investigated the role of dendritic cells (DCs) in endometrial cancer and found that the distribution of different DC subtypes was associated with the grade and stage of the cancer. The study highlights the potential of targeting specific DC subsets for future treatment strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Chu-Xin Li, Yongdan Qi, Yingge Chen, Yu Zhang, Bin Li, Jun Feng, Xian-Zheng Zhang
Summary: Morphology tuning is a powerful strategy to modulate the physiological effects of synthetic biomaterials. This study explores the possibility of morphology tuning in microbe-based biochemicals, using Escherichia coli as an example. The results show that adjusting bacterial morphology can enhance immunogenicity and improve delivery profiles, offering a potential strategy for developing more effective vaccines and carriers.
Article
Engineering, Biomedical
Xue Dong, Pei Pan, Jing-Jie Ye, Qiu-Ling Zhang, Xian-Zheng Zhang
Summary: The study demonstrates a bioactive vaccine platform using hybrid M13 phage and personal tumor antigens for efficient delivery of antigens and activation of immune response. The vaccine not only prevents tumor occurrence but also delays tumor growth, showing potential synergy with immune checkpoint blockade therapy.
Review
Oncology
M. Platten, L. Bunse, W. Wick
Summary: The development of anticancer vaccines has been hindered by a lack of suitable tumor-specific antigens, while IDH1R132H mutation generates a shared clonal neoepitope recognized by mutation-specific T-helper cells, providing new directions for certain cancer vaccines.
Article
Engineering, Biomedical
Yudi Xu, Sheng Ma, Jiayu Zhao, Hongyu Chen, Xinghui Si, Zichao Huang, Zhentao Yu, Wantong Song, Zhaohui Tang, Xuesi Chen
Summary: Using nanotechnology for cancer vaccine design holds great promise, but there are still obstacles to achieving efficient tumor therapeutic effects. This study reports the use of mannan-decorated polymeric nanoparticles as a protein vaccine carrier to elicit robust anticancer immunity. The nanovaccine showed enhanced lymph node draining ability and capturing by dendritic cells, as well as antigen endosome escape and antigen cross-presentation. Excitingly, the nanovaccine alone showed superior anti-tumor effects in murine tumor models.
Article
Oncology
Renato Brito Baleeiro, Peng Liu, Louisa S. Chard Dunmall, Carmela Di Gioia, Ai Nagano, Lauren Cutmore, Jun Wang, Claude Chelala, Lydon Wainaina Nyambura, Peter Walden, Nicholas Lemoine, Yaohe Wang
Summary: This study successfully identified immunogenic neoantigens and generated neoantigen-specific CD8+T cells capable of recognizing human triple-negative breast cancer cells. Using an oncolytic virus as a delivery system, the researchers demonstrated that vaccination with neoantigens can induce a specific CD8+T cell response, slow tumor growth, and increase survival in a mouse model of TNBC. This study provides a promising approach for the development of neoantigen-based immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Yoke Seng Lee, Liam J. O'Brien, Carina M. Walpole, Frances E. Pearson, Ingrid M. Leal-Rojas, Kelly-Anne Masterman, Victoria Atkinson, Andrew Barbour, Kristen J. Radford
Summary: The study found that the number of CD141(+) dendritic cells in the blood of melanoma patients was significantly reduced, and these cells exhibited impaired function after peripheral stimulation. In non-responding patients, the number and function of these cells continued to decline during treatment. Indirectly expanding and activating CD141(+) dendritic cells in vivo with Flt3L and a TLR3 agonist can enhance the efficacy of anti-PD-1 treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Ye Zheng, Xiaoyu Ma, Shouchang Feng, Hongtao Zhu, Xin Chen, Xingjiang Yu, Kai Shu, Suojun Zhang
Summary: Glioblastoma (GBM), the most malignant subtype of glioma, is resistant to traditional therapies and immunotherapies. Dendritic cell vaccine (DCV) has shown potential as a therapeutic method, but there are challenges to its use.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Ji Li, Jiajia Li, Yiwei Peng, Yitian Du, Zhenzhen Yang, Xianrong Qi
Summary: This study developed a nanovaccine platform utilizing dendritic cell derived exosomes carriers and patient-specific neoantigens for individualized cancer immunotherapies. The nanovaccine demonstrated efficient cargo loading and transportation to lymph nodes, inducing potent antigen specific immune responses with high safety. Importantly, it effectively inhibited tumor growth, prolonged survival, and eliminated lung metastasis in melanoma models. Additionally, the exosome-based nanovaccine showed superior antitumor response compared to liposomal formulation due to the presence of exosomal proteins. These findings present a promising strategy for cell free vaccines and personalized nanotechnology in cancer immunotherapy.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Chemistry, Multidisciplinary
Jiayu Zhao, Yudi Xu, Sheng Ma, Yibo Wang, Zichao Huang, Haoyuan Qu, Haochen Yao, Yu Zhang, Guanglu Wu, Leaf Huang, Wantong Song, Zhaohui Tang, Xuesi Chen
Summary: A minimalist binary nanovaccine (BiVax) has been designed to integrate innate stimulating activity into the carrier to elicit robust antitumor immunity, showing promising results in inducing strong immune responses against tumor cells.
ADVANCED MATERIALS
(2022)
Article
Engineering, Biomedical
Hana Wiedermannova, Peter Mudry, Jan Pavlicek, Hana Tomaskova, Andrea Hladikova, Hana Palova, Petra Vesela, Ondrej Slaby, Jaroslav Sterba
Summary: This study aimed to determine the incidence and risk factors of neoplastic diseases in the early stages of life. The results identified medications used by the mother before or during pregnancy and genetic diseases as the highest risk factors for early childhood tumors.
BIOMEDICAL PAPERS-OLOMOUC
(2023)
Article
Oncology
Johannes E. Wolff, Stefaan W. Van Gool, Tezer Kutluk, Blanca Diez, Rejin Kebudi, Beate Timmermann, Miklos Garami, Jaroslav Sterba, Gregory N. Fuller, Brigitte Bison, Uwe R. Kordes
Summary: Standards for chemotherapy against choroid plexus tumors have not yet been established. In this study, Carboplatin/Etoposide/Vincristine (CarbEV) was found to be more effective than Cyclophosphamide/Etoposide/Vincristine (CycEV). Histological grading was the most influential prognostic factor.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Jan Malaska, Jan Stasek, Frantisek Duska, Martin Balik, Jan Maca, Jan Hruda, Tomas Vymazal, Olga Klementova, Jan Zatloukal, Tomas Gabrhelik, Pavel Novotny, Regina Demlova, Jana Kubatova, Jana Vinklerova, Adam Svobodnik, Milan Kratochvil, Jozef Klucka, Roman Gal, Mervyn Singer
Summary: This study aims to compare the efficacy and safety of two different doses of dexamethasone in patients with moderate to severe ARDS undergoing mechanical ventilation. The study will include 300 participants and follow them for 360 days after randomization. The primary endpoint is the number of ventilator-free days at 28 days after randomization.
Review
Oncology
Agata Pastorczak, Andishe Attarbaschi, Simon Bomken, Arndt Borkhardt, Jutte van der Werff ten Bosch, Sarah Elitzur, Andrew R. Gennery, Eva Hlavackova, Arpad Kerekes, Zdenka Krenova, Wojciech Mlynarski, Tomasz Szczepanski, Tessa Wassenberg, Jan Loeffen
Summary: Ataxia Telangiectasia (AT) and Nijmegen breakage syndrome (NBS) are common DNA repair disorders that increase the risk of developing hematological malignancies. Treatment of lymphoproliferative diseases in patients with these disorders is challenging due to the complications of the underlying disorder and the toxicity of chemotherapy. There is a lack of treatment guidelines specifically designed for these patients, but clinical recommendations can be used as a reference.
Article
Oncology
Jutte van der Werff ten Bosch, Eva Hlavackova, Charlotte Derpoorter, Ute Fischer, Francesco Saettini, Sujal Ghosh, Roula Farah, Delfien Bogaert, Rabea Wagener, Jan Loeffen, Chris M. Bacon, Simon Bomken
Summary: This article discusses the causes and complications of inborn errors of immunity (IEI) and emphasizes the importance of recognition of potential IEI by pediatric hemato-oncologists. It provides guidelines for diagnostic tests and treatment options.
PEDIATRIC HEMATOLOGY AND ONCOLOGY
(2023)
Article
Medicine, General & Internal
Milos Holanek, Iveta Selingerova, Pavel Fabian, Oldrich Coufal, Ondrej Zapletal, Katarina Petrakova, Tomas Kazda, Roman Hrstka, Alexandr Poprach, Maria Zvarikova, Ondrej Bilek, Marek Svoboda
Summary: This retrospective study suggests that residual cancer burden after neoadjuvant therapy is associated with worse treatment outcomes in breast cancer patients. The study evaluated the dynamics and impact of biomarkers on long-term outcomes in specific breast cancer subtypes. The proliferation index Ki-67 was significantly altered by neoadjuvant therapy and predicted survival outcomes in different subtypes.
Article
Biochemistry & Molecular Biology
Andrea Martisova, Lucia Sommerova, Adam Krejci, Iveta Selingerova, Tamara Kolarova, Filip Zavadil Kokas, Milos Holanek, Jan Podhorec, Tomas Kazda, Roman Hrstka
Summary: The TGF-beta signaling pathway and AGR2 downregulation play important roles in focal adhesion formation and cancer cell migration and invasion. In addition, AGR2 is identified as a crucial component of the arachidonic acid metabolic pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Meeting Abstract
Oncology
T. Kazda, P. Fadrus, I Selingerova, R. Jancalek, P. Pospisil, L. Hynkova, J. Garcic, V. Vybihal, I Roskova, R. Belanova, M. Smrcka, M. Svajdova, P. Slampa
Article
Oncology
Dominik Karres, Giovanni Lesa, Franca Ligas, Sylvie Benchetrit, Sara Galluzzo, Karen Van Malderen, Jaroslav Sterba, Maaike van Dartel, Marleen Renard, Peter Sisovsky, Siri Wang, Koen Norga
Summary: Regulatory decisions on paediatric investigation plans (PIPs) are crucial for providing effective and safe medicines for children with unmet medical needs, particularly in the field of paediatric oncology. Coordinating with stakeholders is essential for prioritizing and accelerating drug development in this challenging area.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Lucie Gabrielova, Iveta Selingerova, Jan Zatecky, Ondrej Zapletal, Petr Burkon, Milos Holanek, Oldrich Coufal
Summary: This study compares different localization systems for detecting tumor lesions in the breast and finds apparent differences and small nuances not yet observed in clinical practice.
CLINICAL BREAST CANCER
(2023)
Article
Oncology
Peter Grell, Simona Borilova, Pavel Fabian, Iveta Selingerova, David Novak, Petr Muller, Igor Kiss, Rostislav Vyzula
Summary: Immunotherapy has revolutionized the treatment of malignant melanoma and non-small cell lung cancer in the last decade. However, a significant proportion of patients do not benefit from checkpoint inhibitor treatment, necessitating the search for new biomarkers to predict treatment response. This study aimed to analyze tumor tissue and immune profiles to identify predictive biomarkers for immune checkpoint inhibitor treatment.
Article
Environmental Sciences
Petra Musilova, Dita Kadlcikova, Hana Hradska, Miluse Vozdova, Iveta Selingerova, Halina Cernohorska, Dusan Salat, Jiri Rubes
Summary: This study compared chromosome damage in city policemen from three cities in the Czech Republic and found that air pollution, especially during the winter season, has a negative impact on chromosomes.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
(2023)
Meeting Abstract
Respiratory System
J. Nevrlka, I. Selingerova, Z. Nevrlkova, K. Ditetova, L. Zdrazilova-Dubska
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Oncology
Michal Rihacek, Iveta Selingerova, Ivo Kocak, Ilona Kocakova, Eva Rihackova, Dalibor Valik, Jaroslav Sterba
Summary: This study retrospectively analyzed the data of adult and pediatric patients treated with sunitinib, and found that sunitinib treatment increased the mean corpuscular volume of erythrocytes. The study also found that the rate of increase was faster in patients who experienced treatment-related adverse events.
Article
Oncology
Petra Pokorna, Giannoula Lakka Klement, Alzbeta Vasikova, Veronika Kanderova, Marta Jezova, Kristyna Noskova, Peter Mudry, Michal Kyr, Tomas Merta, Viera Bajciova, Zdenka Krenova, Hana Palova, Dalibor Valik, Lenka Zdrazilova Dubska, Ondrej Slaby, Jaroslav Sterba
JCO PRECISION ONCOLOGY
(2022)